Gamow-Teller transitions from 56 Ni Masaki Sasano RIKEN Nishina Center.
OOTR SessionII Sasano
Transcript of OOTR SessionII Sasano
-
8/12/2019 OOTR SessionII Sasano
1/15
Prognostic and PredictivePrognostic and Predictive
BreastBreast CancerCancer
Hironobu Sasano, MD
Tohoku University Graduate School of Medicine,
-
8/12/2019 OOTR SessionII Sasano
2/15
e e n on o ar y reas ancer
enera
consensus:
pT1N0M0
Tumor 2.0 cm or less in greatest dimension
m c: m cro nvas on . cm or ess
T1a: 0.1 cm to 0.5 cm in greatest dimension
T1b: 0.5 cm to 1.0 cm in greatest dimension
T1c: 1.0 cm to 2.0 cm in greatest dimension
The size of the tumor is still one of the most
.
Fewer than 2% of T1a/T1bN0M0 patients wil l die of diseasewithin 5 yearsBreast. In: American Joint Committee on Cancer.: AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer, 2002, pp 171-180.
-
8/12/2019 OOTR SessionII Sasano
3/15
-
8/12/2019 OOTR SessionII Sasano
4/15
Distinction Between Prognostic &
Predictive Factors
100105
Luminal A
Disease-Free Survival Prognosis in Japanese Patients
7580
8590 Luminal B
HER2
Basal
50556065 Unclassified
Trastuzumab
0 25 50 75 100 1253540 prognosis
Luminal A vs HER2: P = .0059
Luminal B vs HER2: P = .0046
-
8/12/2019 OOTR SessionII Sasano
5/15
N tti h difi ti ftti h difi ti f
o s an ar o rognos c ac ors
Nottingham modification ofottingham modification of
loom and Richardsonloom and Richardson
Tubular formation>75% of the tumor 1 10% to 75% 2
-
8/12/2019 OOTR SessionII Sasano
6/15
-
8/12/2019 OOTR SessionII Sasano
7/15
Biological Behavior of Carcinoma
Invasion Cell proliferation
In early breast cancer, cell proliferation
status is considered to la more im ortant
roles in biological behavior
-
8/12/2019 OOTR SessionII Sasano
8/15
-
8/12/2019 OOTR SessionII Sasano
9/15
-
8/12/2019 OOTR SessionII Sasano
10/15
-
8/12/2019 OOTR SessionII Sasano
11/15
-
8/12/2019 OOTR SessionII Sasano
12/15
Oncotype DX
Stage I & II ER(+), LN(-) patients: recurrence risks
and addit ive chemotherapy + tamoxifen treatment
Can be classified into low-risk, intermediate-risk, & high-risks patients
-
Paik S, et al. N Engl J Med. 2004;351:2817-2826. Paik S, et al. J Clin Oncol. 2006;24:3726-3734.
May need more studies for incorporation
-
8/12/2019 OOTR SessionII Sasano
13/15
What you can do in the management of
earl breast cancer in our dail ractice
sFOUR precise evaluations
in the resected s ecimens
for the benefits of the patients
-
8/12/2019 OOTR SessionII Sasano
14/15
1. Precise measurement of the size
.
Nottingham s criteria
-
8/12/2019 OOTR SessionII Sasano
15/15